Appeals court revives suit against Sanofi's Genzyme over access to Fabry disease drug
20 Feb 2024
AcquisitionPatent Infringement
An appeals court ruling from late last week will revive a lawsuit over a Sanofi subsidiary’s contamination issues and a subsequent shortage of a key rare disease drug.
At issue in the case is a series of alleged blunders related to the supply of Genzyme’s drug for treating Fabry disease, a rare neurological disorder that can lead to kidney failure, heart failure or stroke.
The revived lawsuit, filed in 2020 in a Massachusetts federal court, seeks monetary damages for more than two dozen Fabry patients who allege they were injured by the company’s handling of the contamination and subsequent shortage of the drug, marketed as Fabrazyme, that occurred between 2009 and 2012. Sanofi
acquired
Genzyme for about $20 billion in 2011.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.